2011
DOI: 10.1159/000334430
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the Efficacy and Safety of the Combination of Gemcitabine and Nedaplatin for Elderly Patients with Advanced Non-Small-Cell Lung Cancer

Abstract: Objective: The aim of the present study was to retrospectively assess the safety and efficacy of the combination of gemcitabine and nedaplatin in elderly patients with advanced non-small-cell lung cancer (NSCLC). Methods: Patients ≧75 years with previously untreated NSCLC who underwent chemotherapy consisting of gemcitabine (800 mg/m2 on days 1 and 8) and nedaplatin (80 mg/m2 on day 1) every 3 weeks were retrospectively analyzed. Results: Of the 35 patients, 28 were men and 7 were women, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
7
0

Year Published

2013
2013
2016
2016

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 59 publications
1
7
0
Order By: Relevance
“…When diagnosed, only < 20% NSCLC patients could receive surgeries and fewer with radiotherapy, and most are in advanced ones with distant metastasis who missed the optimal surgical opportunities except the systemic chemotherapies. Studies demonstrated that the third generation of cytotoxic drugs concomitant with cisplatins and chemotherapies were the optimal choices for treating middle and advanced NSCLC (Sugiyama et al, 2011;Terret et al, 2011), which played a critical and important role in controlling disease progression, alleviating clinical symptoms, improving patients' quality of life (QOL) and prolonging their survival time, etc.. However, appropriate chemotherapeutic protocols and drugs are extremely important due to frequently occurred distant metastasis and recurrence according to complex biological properties and poor immunity in old and weak patients.…”
Section: Discussionmentioning
confidence: 99%
“…When diagnosed, only < 20% NSCLC patients could receive surgeries and fewer with radiotherapy, and most are in advanced ones with distant metastasis who missed the optimal surgical opportunities except the systemic chemotherapies. Studies demonstrated that the third generation of cytotoxic drugs concomitant with cisplatins and chemotherapies were the optimal choices for treating middle and advanced NSCLC (Sugiyama et al, 2011;Terret et al, 2011), which played a critical and important role in controlling disease progression, alleviating clinical symptoms, improving patients' quality of life (QOL) and prolonging their survival time, etc.. However, appropriate chemotherapeutic protocols and drugs are extremely important due to frequently occurred distant metastasis and recurrence according to complex biological properties and poor immunity in old and weak patients.…”
Section: Discussionmentioning
confidence: 99%
“…At present, the chemotherapeutic protocols for NSCLC mainly apply platinums as basic drugs combining with the third generation chemotherapeutic drugs such as paclitaxel, gemcitabine and vinorelbine, etc.. Multiple randomized clinical trials showed that the first-line treatment of double-drug protocol containing platinum had similar clinical effect on malignant tumors, for which the main differences were toxic characteristics and treatment costs (Sugiyama et al, 2011;Teramoto et al, 2012;Wang et al, 2012;He et al, 2013). Gemcitabine, a new-type of deoxycytidine analogue, can not only be used to inhibit ribonucleotide reductase to form hidden chains but also to improve cell apoptosis by rupturing the synthesis of DNA double chains.…”
Section: Discussionmentioning
confidence: 99%
“…There were no differences in response rate and survival between patients aged 75-79 years and patients ≥80 years, although grade 3-4 thrombocytopenia and anemia were significantly more frequent in patients ≥80 years (Sugiyama et al, 2011). In conclusion, this study indicated that the combination of gemcitabine and nedaplatin is effective and well tolerated for selected elderly patients with advanced NSCLC (Sugiyama et al, 2011). In a study by Masago.…”
Section: Discussionmentioning
confidence: 56%
“…Via steps of screening the title and reading the abstract, 4 studies were identified (Shirai et al, 2006;Masago et al, 2011;Sugiyama et al, 2011;Yang et al, 2012). These studies had been carried out in Japan and in China.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation